Scancell Holdings plc (LON:SCLP – Get Free Report) hit a new 52-week high on Monday . The company traded as high as GBX 25.50 and last traded at GBX 25, with a volume of 8427769 shares. The stock had previously closed at GBX 22.77.
Scancell Price Performance
The business has a 50 day moving average price of GBX 13.55 and a two-hundred day moving average price of GBX 12.04. The stock has a market cap of £259.45 million, a PE ratio of -45.45 and a beta of 0.57. The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
